Fuefuki, Japan

Atsushi Sugiyama


Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Fuefuki, JP (2012)
  • Bunkyo-ku, JP (2014)

Company Filing History:


Years Active: 2012-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Atsushi Sugiyama

Introduction

Atsushi Sugiyama is a notable inventor based in Fuefuki, Japan. He has made significant contributions to the field of myocardial toxicity examination through his innovative inventions. With a total of 2 patents, Sugiyama's work focuses on developing methods and devices that enhance the evaluation of drug effects on heart cells.

Latest Patents

Sugiyama's latest patents include a "Device for Examining Myocardial Toxicity" and a "Chip for Examining Myocardial Toxicity." These inventions provide a means to conduct in vitro examinations that parallel traditional in vivo methods. The device utilizes a cell population arranged on a transparent substrate, allowing for the assessment of drug effects on myocardial pulsating cells and fibroblast cells. His work also includes a model cell chip that enables on-chip evaluation of drug effects on hERG-expressing cells, facilitating in vitro myocardial toxicity testing.

Career Highlights

Throughout his career, Atsushi Sugiyama has worked with esteemed organizations such as Tokyo Medical and Dental University and Mitsubishi Chemical Medience Corporation. His experience in these institutions has contributed to his expertise in the field of myocardial toxicity and drug evaluation.

Collaborations

Sugiyama has collaborated with notable colleagues, including Kenji Yasuda and Tomoyuki Kaneko. These partnerships have further enriched his research and development efforts in the area of myocardial toxicity.

Conclusion

Atsushi Sugiyama's innovative contributions to the examination of myocardial toxicity demonstrate his commitment to advancing medical research. His patents reflect a significant step forward in the evaluation of drug effects on heart cells, paving the way for improved safety in pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…